Brett Kiedaisch

Brett Kiedaisch is an experienced professional in analytical development and quality control, currently serving as Associate Director at Nanoscope Therapeutics Inc. since April 2024. Previously, Brett held positions including Associate Director/Director at Senti Biosciences, where responsibilities included leading the Analytical Development group for CAR-NK programs, developing testing strategies, and building a high-functioning team. Additional experience includes roles at Stanford University School of Medicine, Smith & Nephew, and Healthpoint Biotherapeutics, focusing on the development and quality control of cell and gene therapies. Brett's academic background includes a Master’s degree in Biology with a focus on Plant Cell Wall Development and a Bachelor’s degree in Cell & Molecular Biology, both from Texas Tech University.